ImmunityBio: FDA Approval Potential In May Of 2023

Apr. 12, 2023 4:08 PM ETImmunityBio, Inc. (IBRX) StockIBRX172 Comments
Terry Chrisomalis
Investing Group Leader

Summary

  • ImmunityBio, Inc. has a PDUFA date of May 23, 2023, for potential FDA approval of N-803 + BCG for the treatment of patients with BCG-unresponsive CIS non-muscle invasive bladder cancer.
  • It is said that the global bladder cancer market could reach $11.5 billion by 2032.
  • Initiation of phase 3 study using N-803 in localized BCG-unresponsive NMIBC papillary disease expected in 2023.
  • Initiation of phase 3 study using N-803 in combination with PD-L1 therapy t-haNK, and aldoxorubicin for the treatment of patients with 3rd-line locally advanced or metastatic pancreatic cancer expected in 2023.
  • This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

Glass test tubes filled with liquid on rack for an experiment in science research lab

RTsubin/iStock via Getty Images

ImmunityBio, Inc. (NASDAQ:IBRX) is a great speculative biotech play to look into. That's because I believe there is huge potential based on the fact that there is one major catalyst approaching in a few

This article is published by Terry Chrisomalis, who runs the >Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.5K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About IBRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on IBRX

Related Stocks

SymbolLast Price% Chg
IBRX
--
Compare

Trending Analysis

Trending News